Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- High Grade Serous Ovarian CancerTriple Negative Breast CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- A2A Pharmaceuticals Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT06136884
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Oklahoma Univeristy, Oklahoma City, Oklahoma, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
News
No news found